17:35 , Jul 17, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Cancer; melanoma; colorectal cancer Cell culture and mouse studies suggest inhibiting PVR could help treat cancer. In patient tissue samples, tumor levels of PVR mRNA were higher than in the corresponding normal tissues. In a...
20:06 , Jul 13, 2018 |  BC Week In Review  |  Clinical News

Istari reports Phase I survival data for glioblastoma candidate

Istari Oncology Inc. (Research Triangle Park, N.C.) reported data from 61 patients with recurrent glioblastoma in a Phase I trial showing that Pvsripo led to a median overall survival (OS) of 12.5 months vs. 11.3...
04:55 , Jan 19, 2018 |  BC Week In Review  |  Clinical News

Eiger discontinues ubenimex for PAH

Eiger BioPharmaceuticals Inc. (NASDAQ:EIGR) discontinued development of ubenimex to treat pulmonary arterial hypertension (PAH). The company made the decision after the product missed the primary endpoint in the Phase II LIBERTY trial in the indication. Eiger...
19:51 , Jan 16, 2018 |  BC Extra  |  Clinical News

Phase II PAH readout sinks Eiger shares

Eiger BioPharmaceuticals Inc. (NASDAQ:EIGR) lost $7.90 (49%) to $8.10 Tuesday after discontinuing development of ubenimex to treat pulmonary arterial hypertension. The company made the decision after the product missed the primary endpoint in the Phase...
23:46 , Jul 13, 2017 |  BC Week In Review  |  Clinical News

Arena's ralinepag meets primary in Phase II for PAH

Arena Pharmaceuticals Inc. (NASDAQ:ARNA) reported top-line data from the Phase II APD811-003 trial in 61 patients with pulmonary arterial hypertension (PAH) showing that oral ralinepag (APD811) met the primary endpoint of improving the absolute change...
01:56 , Jul 11, 2017 |  BC Extra  |  Clinical News

Arena rises after hours on Phase II PAH data

Arena Pharmaceuticals Inc. (NASDAQ:ARNA) jumped $7.60 (41%) to $25.99 in after-hours trading Monday after it said ralinepag (APD811) significantly improved absolute change from baseline in pulmonary vascular resistance (PVR) in a Phase II trial to...
19:10 , May 19, 2017 |  BC Week In Review  |  Clinical News

Eiger completes enrollment in Phase II to treat PAH

Eiger BioPharmaceuticals Inc. (NASDAQ:EIGR) completed enrollment of 61 patients with pulmonary arterial hypertension (PAH) in the North American Phase II LIBERTY trial evaluating Bestatin ubenimex plus standard of care (SOC). Patients in the double-blind, placebo-controlled...
00:28 , Mar 31, 2017 |  BC Innovations  |  Targets & Mechanisms

Cells on the rise

This year’s meeting of the American Association for Cancer Research (AACR) will keep the spotlight on immuno-oncology, where preclinical science is continuing to expand the use of different types of innate and adaptive immune cells...
21:44 , Feb 1, 2017 |  BC Week In Review  |  Clinical News

Bestatin: LIBERTY2 extension study started

Eiger began the open-label LIBERTY2 extension study of oral Bestatin for ≥24 weeks in about 45 patients who completed the double-blind, placebo-controlled, North American Phase II LIBERTY trial, which is evaluating thrice-daily 150 mg Bestatin...
22:11 , Dec 13, 2016 |  BC Week In Review  |  Clinical News

Ralinepag: Completed Ph II enrollment

Arena completed enrollment of about 60 patients in a 22-week, double-blind, placebo-controlled, international Phase II trial evaluating oral ralinepag. Arena Pharmaceuticals Inc. (NASDAQ:ARNA), San Diego, Calif.  Product: Ralinepag (APD811)  Business: Cardiovascular  Molecular target: Prostacyclin (IP) receptor (PGI2; PTGIR)  Description: PGI2...